↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Odyssey Therapeutics$ODTX · filed: 🫧 Edgar looked up Odyssey TherapeuticsCheck ▾Close ▴
What Odyssey Therapeutics filed
🫧 Edgar looked up Odyssey Therapeutics, Inc. ($ODTX). Last filing: 10-Q, 2026-11-04. 7 event filings (8-K) in the past twelve months. Every figure links to the filing it came from on Odyssey Therapeutics’s card.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Odyssey Therapeutics prices **$225M** IPO this week with 16-month cash runway and three autoimmune assets in early development.
$225 million
IPO on Tuesday
$14 to $16
per share
ZCTA-01
a monoclonal antibody targeting a novel immune checkpoint in…
ZCTA-03
a small molecule inhibitor for ulcerative colitis entering Phase…
Odyssey Therapeutics filed terms for a $225 million IPO on Tuesday, offering 15 million shares at $14 to $16 per share. The Boston-based biotech develops precision medicines for autoimmune diseases and expects to list on Nasdaq under the ticker ODTX by Friday. Morgan Stanley and Jefferies are leading the offering.
The company carries three assets into public markets: ZCTA-01, a monoclonal antibody targeting a novel immune checkpoint in Phase 1 for systemic lupus; ZCTA-03, a small molecule inhibitor for ulcerative colitis entering Phase 1 next quarter; and an undisclosed preclinical program. Odyssey burned $87 million in cash during the nine months ended September 2024 and reported $142 million in cash at quarter-end. The company posted a $91 million net loss for that period on zero revenue. Management projects the IPO proceeds plus existing cash will fund operations into Q3 2026, enough to deliver Phase 1b data for ZCTA-01 and initiate two additional trials.
The offering matters because autoimmune biotech has tightened into oligopoly at the top while early-stage names struggle for non-dilutive capital. AbbVie's Skyrizi and Rinvoq franchise posted $14.2 billion in combined 2024 sales, up 41% year-over-year, creating a gravitational pull for institutional buyers toward established brands. Odyssey's $1.05 billion post-money valuation at midpoint prices the company at 12x its current cash position, a multiple that works only if ZCTA-01 data arrives clean and on time. Bain Capital Life Sciences owns 38% pre-offering and will retain 31% post-deal, a concentration that limits float and amplifies volatility in the first six months of trading. The company's burn rate implies 16 months of runway post-IPO without additional financing, which means a secondary offering or partnership announcement likely arrives before the ZCTA-01 Phase 2 readout in mid-2026.
Allocators should track three events: the ZCTA-01 Phase 1b safety data expected in Q1 2025, which will determine whether institutions build positions or fade the name; the ZCTA-03 Phase 1 initiation in Q2 2025, which tests management's ability to execute on multiple programs simultaneously; and any partnership or licensing discussions around the undisclosed preclinical asset, which could provide non-dilutive capital before the next secondary. The competitive landscape tightens in Q4 2025 when two other autoimmune biotechs—Prometheus Biosciences under Merck and Ventyx Biosciences—report mid-stage data that will reset valuation benchmarks across the sector.
The IPO prices into a market that has already absorbed $4.1 billion in biotech offerings this quarter, with 72% of those deals trading below issue price after 90 days. Odyssey's execution risk is timing, not science.
Branded by POPS4 · proof in 60 seconds
For the principal
Pass on the IPO; revisit post-Phase 1b data in Q1 2025 when institutional positioning becomes clear.
For the operator
Watch the first 90-day trading pattern and Bain's lock-up behavior; real entry is post-data, not launch.
For the house
Tracking for Huang Goodman Healthcare Fund; no position until ZCTA-01 safety readout confirms institutional appetite.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.